RxDoctor Payments Data

David Scott, MD

Adult Reconstructive Orthopaedic Surgery · Spokane, WANPI 1093812778

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $597,714 of the $670,954 with a category attached, or 89.1%. Medacta USA, Inc. accounts for 91.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $226,847 and has fallen 67.9% since, to $72,888 in 2025.

$670,954in general payments, 2019–2025

Across 297 payments — averaging $2259.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medacta USA, Inc.$613K
  • Microport Orthopedics Inc$30K
  • UOC USA Inc$12K
  • Zimmer Biomet$8K
  • Nextstep Arthropedix, LLC$7K
  • Stryker$162
  • plus $474 from 8 others
$3,247,492in research payments, 2019–2025

Across 192 payments — averaging $16,914 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medacta USA, Inc.$3.1M
  • Microport Orthopedics Inc$114K
  • Molnlycke Health Care US, LLC$29K
  • Stryker$24K
  • GSK$14K

What the payments were for

  • Consulting fees$597,71489%
  • Speaking & faculty fees$23,9004%
  • Travel & lodging$37,5536%
  • Food & beverage$11,7662%
  • Education$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult reconstructive orthopaedic surgery providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$136,137
Medicare patients
202
Services billed
1,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin11$4,165
Amoxicillin95$214
Clindamycin Hcl16$68

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →